MTOR Mutation

CI-VAR-00002660Explore in graph →CIViC 277

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
MTOR Mutation	Everolimus + PazopanibCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID705 A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in… (full text at CIViC) PMID 24625776 · Wagle et al., 2014 · Open in CIViC	civic
Melanoma1
MTOR Mutation	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID712 Median overall survival of patients with nonsynonymous mutations in mTOR was shorter. PMID 26490311 · Kong et al., 2016 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Solid Neoplasm1
MTOR Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation	Sapanisertib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12075 In this study, 30 patients with advanced solid malignancies harboring mTOR/AKT/PI3K pathway alterations were treated with Sapanisertib. The tumor types included sarcomas, breast, ovarian, head and nec… (full text at CIViC) PMID 38126764 · Subbiah et al., 2024 · Open in CIViC	civic